Effects of chemokine (C-C motif) receptor 2 and 3 antagonists in rat models of hemorrhagic shock.

Effects of chemokine (C-C motif) receptor 2 and 3 antagonists in rat models of hemorrhagic shock.
复制标题

DOI:
10.1371/journal.pone.0284472
复制
发表时间:
2023
期刊:
影响因子:
3.7
通讯作者:
Majetschak, Matthias
Majetschak, Matthias
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Weche, McWayne;DeSantis, Anthony J.;McGee, Michelle Y.;Enten, Garrett A.;Gao, Xianlong;Majetschak, Matthias

文献摘要

参考文献

相似文献

趋化因子 CCL2(趋化因子受体 CCR2/3/5 的激动剂)的全身浓度与创伤失血性休克后的血流动力学不稳定有关。我们之前报道过,CCR2 拮抗剂 INCB3284 可预防心血管衰竭并减少失血性休克 (HS) 30 分钟后的液体需求,而 CCR5 拮抗剂 Maraviroc 则无效。 HS 后 CCR3 阻断的效果尚不清楚,并且缺乏有关 INCB3284 在较长时间的 HS 后以及在没有液体复苏 (FR) 的 HS 模型中的治疗潜力的信息。本研究的目的是评估 SB328437 阻断 CCR3 的效果,并进一步明确 INCB3284 的治疗效果。在系列 1-3 中,Sprague-Dawley 大鼠失血至平均动脉血压 (MAP) 为 30mmHg,随后进行 FR 至 MAP 60mmHg 或收缩压 90mmHg。系列 1:30 分钟 HS 和 FR,直到 t = 90 分钟。 SB328437 在 t = 30 分钟时剂量依赖性地减少液体需求 >60%。系列 2:60 分钟 HS 和 FR,直到 t = 300 分钟。 INCB3284 和 SB328437 在 t = 60 分钟时分别减少液体需求超过 65%(p < 0.05 与载体)和 25%(p > 0.05 与载体),直到 t = 220 分钟。此后,所有动物对液体的需求量急剧增加。 SB328437 的中位生存时间为 290 分钟,媒介物和 INCB3284 治疗后 >300 分钟(p<0.05)。系列 3:HS/FR 与系列 2 相同。INCB3284 在 t = 60 分钟和 t = 200 分钟时将液体需求量减少了 75%,直到 t = 300 分钟(与车辆相比,p<0.05)。媒介物治疗组死亡率为 70%,INCB3284 治疗组死亡率为零 (p<0.05)。系列 4:INCB3284 和 SB328437 不影响无 FR 的致死 HS 模型中的生存​​时间。我们的研究结果进一步支持这样的假设,即阻断主要 CCL2 受体 CCR2 是改善 HS 后 FR 的一种有前途的方法,并证明 INCB3284 的剂量可以优化。
Systemic concentrations of chemokine CCL2, an agonist at chemokine receptors CCR2/3/5, have been associated with hemodynamic instability after traumatic-hemorrhagic shock. We reported previously that the CCR2 antagonist INCB3284 prevents cardiovascular collapse and reduces fluid requirements after 30min of hemorrhagic shock (HS), whereas the CCR5 antagonist Maraviroc was ineffective. The effects of CCR3 blockade after HS are unknown and information on the therapeutic potential of INCB3284 after longer periods of HS and in HS models in the absence of fluid resuscitation (FR) is lacking. The aims of the present study were to assess the effects of CCR3 blockade with SB328437 and to further define the therapeutic efficacy of INCB3284. In series 1–3, Sprague-Dawley rats were hemorrhaged to a mean arterial blood pressure (MAP) of 30mmHg, followed by FR to MAP of 60mmHg or systolic blood pressure of 90mmHg. Series 1: 30min HS and FR until t = 90min. SB328437 at t = 30min dose-dependently reduced fluid requirements by >60%. Series 2: 60min HS and FR until t = 300min. INCB3284 and SB328437 at t = 60min reduced fluid requirements by more than 65% (p<0.05 vs. vehicle) and 25% (p>0.05 vs. vehicle), respectively, until t = 220min. Thereafter, all animals developed a steep increase in fluid requirements. Median survival time was 290min with SB328437 and >300min after vehicle and INCB3284 treatment (p<0.05). Series 3: HS/FR as in series 2. INCB3284 at t = 60min and t = 200min reduced fluid requirements by 75% until t = 300min (p<0.05 vs. vehicle). Mortality was 70% with vehicle and zero with INCB3284 treatment (p<0.05). Series 4: INCB3284 and SB328437 did not affect survival time in a lethal HS model without FR. Our findings further support the assumption that blockade of the major CCL2 receptor CCR2 is a promising approach to improve FR after HS and document that the dosing of INCB3284 can be optimized.
DOI: 10.1002/1873-3468.14463
发表时间: 2022-10
期刊: FEBS LETTERS
影响因子: 3.5
作者:
Gao, Xianlong;DeSantis, Anthony J.;Enten, Garrett A.;Weche, McWayne;Marcet, Jorge E.;Majetschak, Matthias
通讯作者: Majetschak, Matthias
DOI: 10.4049/jimmunol.181.4.2806
发表时间: 2008-08-15
影响因子: 4.4
作者:
Hsieh, Chi-Hsun;Frink, Michael;Chaudry, Irshad H.
通讯作者: Chaudry, Irshad H.
DOI: 10.1021/ml200030q
发表时间: 2011-06-01
影响因子: 4.2
作者:
Xue, Chu-Biao;Feng, Hao;Metcalf, Brian
通讯作者: Metcalf, Brian
DOI: 10.1111/1440-1681.12958
发表时间: 2018-04-27
影响因子: 2.9
作者:
Nassoiy SP;Babu FS;LaPorte HM;Byron KL;Majetschak M
通讯作者: Majetschak M
蛋白酶体抑制可延长大鼠致死性出血性休克期间的生存。
DOI: 10.1097/ta.0b013e31827d5db2
发表时间: 2013-02
期刊: The journal of trauma and acute care surgery
影响因子: --
作者:
Bach HH 4th;Laporte HM;Wong YM;Gamelli RL;Majetschak M
通讯作者: Majetschak M